MECP2 and neoplasm: Zhou et al. [70] investigated the breast cancer cell line MCF-7 along with tumor tissue samples to show that linc-ROR promotes the survival of breast cancer cells during rapamycin treatment by functioning as a ceRNA sponge for miR-194-3p, which targets the methyl-CpG binding protein 2 (MECP2).